BioSpace News Archive

Guardant Health, along with researchers with MD Anderson Cancer Center, the Samsung Medical Center and others, conducted a large study that showed the Guardant360 assay can accurately detect MSI.

Canada’s primary pharmaceutical lobby group, Innovative Medicines Canada, urged the Canadian government to respond to the U.S. plans before it caused drug shortages in Canada. An earlier version of its briefing called for a government ban of all drug exports “unless otherwise permitted by regulation.”

Verona Pharma plc, a biopharmaceutical company focused on respiratory diseases, announces positive Phase 2 data with a dry powder inhaler formulation of its lead development product, ensifentrine, for the maintenance treatment of chronic obstructive pulmonary disease.

First patient enrolment at University of Cincinnati

The approval is for only “select” patients where surgery isn’t an option. It also comes with a Boxed Warning for liver toxicity, which has been a problem in several clinical trials with the drug.

The goal of the trial was to evaluate the efficacy and safety of the drug in patients six years of age and older with SCD who were hospitalized for a vaso-occlusive crisis and required treatments with intravenous opioids.

Roche announced interim results from its Phase III IMvigor130 clinical trial, indicating it met its co-primary endpoint of progression-free survival. The trial evaluated the combination of Tecentriq and platinum-based chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma compared to chemotherapy alone.

Yardi Matrix recently published an analysis of the Boston office market that was more comprehensive than just the life sciences market, but paints a good picture of what the commercial real estate market is like there as well. Here’s a look.

Company strengthens board ahead of trial results in type 1 diabetes patients and expansion of indications for its proprietary Imotope™ technology

The owners of Cytena GmbH have agreed to sell all Cytena shares to CELLINK AB for a purchase price of 30.25M euros.